Literature DB >> 15265953

Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells.

Emanuele Durante-Mangoni1, RuoJie Wang, Angela Shaulov, Qi He, Imad Nasser, Nezam Afdhal, Margaret J Koziel, Mark A Exley.   

Abstract

A subset of CD161(+)CD56(+/-) NKT cells can recognize glycolipids presented by CD1d and positively or negatively regulate inflammatory responses, including those implicated in several models of hepatitis. CD1d is expressed at very low levels in the healthy liver, but there is a large fraction of CD161(+)CD56(+) NKT cells. There are high levels of nonclassical proinflammatory hepatic CD1d-reactive T cells in hepatitis C virus (HCV) infection. Hepatic inflammatory cells and biliary cells adjacent to portal tract fibrotic areas of HCV-infected donors specifically up-regulated CD1d. A hepatocyte cell line expressing minimal CD1d was efficiently recognized by hepatic CD1d-reactive T cells, suggesting a role for these cells in disease. Hepatic CD1d-reactive T cells from HCV-positive as well as negative donors produced large amounts of IFN-gamma with some IL-13, but only rarely detectable IL-4. We confirmed large numbers of hepatic CD161(+) T cells, lower levels of CD56(+) T cells, and small numbers of classic invariant NKT cells. However, hepatic CD1d-reactivity was not restricted to any of these populations. We suggest virally infected hepatic cells can process potent CD1d-presented liver Ag(s), for surveillance by resident Th1 hepatic CD1d-reactive T cells. This process may be beneficial in acute viral clearance, but in chronic infection could contribute to liver injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265953     DOI: 10.4049/jimmunol.173.3.2159

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

Authors:  Miroslaw Kornek; Michael Lynch; Shruti H Mehta; Michelle Lai; Mark Exley; Nezam H Afdhal; Detlef Schuppan
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

2.  Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.

Authors:  Angela Shaulov; Simon Yue; Ruojie Wang; Robin M Joyce; Steven P Balk; Haesook T Kim; David E Avigan; Lynne Uhl; Robert Sackstein; Mark A Exley
Journal:  Exp Hematol       Date:  2008-02-08       Impact factor: 3.084

Review 3.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

4.  Enhanced oxidative phosphorylation in NKT cells is essential for their survival and function.

Authors:  Ajay Kumar; Kalyani Pyaram; Emily L Yarosz; Hanna Hong; Costas A Lyssiotis; Shailendra Giri; Cheong-Hee Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-25       Impact factor: 11.205

5.  Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.

Authors:  K Yanagisawa; S Yue; H J van der Vliet; R Wang; N Alatrakchi; L Golden-Mason; D Schuppan; M J Koziel; H R Rosen; M A Exley
Journal:  J Viral Hepat       Date:  2013-03-11       Impact factor: 3.728

Review 6.  Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset.

Authors:  Suryasarathi Dasgupta; Vipin Kumar
Journal:  Immunogenetics       Date:  2016-07-12       Impact factor: 2.846

Review 7.  Targeting the diverse immunological functions expressed by hepatic NKT cells.

Authors:  Caroline C Duwaerts; Stephen H Gregory
Journal:  Expert Opin Ther Targets       Date:  2011-05-13       Impact factor: 6.902

8.  Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response.

Authors:  Jie Zhao; Xiufang Weng; Sreya Bagchi; Chyung-Ru Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 9.  Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment.

Authors:  Giuseppe Castello; Susan Costantini; Stefania Scala
Journal:  J Transl Med       Date:  2010-11-03       Impact factor: 5.531

10.  Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo.

Authors:  Simon C Yue; Michael Nowak; Angela Shaulov-Kask; RuoJie Wang; Dominic Yue; Steven P Balk; Mark A Exley
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.